Barclays Raises Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $180.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price boosted by Barclays from $164.00 to $180.00 in a research note issued to investors on Wednesday morning, The Fly reports. The brokerage currently has an overweight rating on the specialty pharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. Royal Bank of Canada set a $184.00 price target on shares of Jazz Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, July 3rd. Zacks Investment Research cut shares of Jazz Pharmaceuticals from a buy rating to a hold rating in a research note on Monday, May 6th. BidaskClub upgraded shares of Jazz Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, July 18th. Oppenheimer set a $176.00 target price on shares of Jazz Pharmaceuticals and gave the stock a buy rating in a research note on Monday, July 8th. Finally, HC Wainwright reiterated a hold rating and issued a $153.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, May 10th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $176.53.

Shares of Jazz Pharmaceuticals stock traded up $0.25 on Wednesday, reaching $137.37. 282,949 shares of the company traded hands, compared to its average volume of 439,758. Jazz Pharmaceuticals has a 52 week low of $113.52 and a 52 week high of $178.32. The business has a 50 day moving average of $138.10. The stock has a market cap of $7.74 billion, a price-to-earnings ratio of 11.22, a PEG ratio of 1.14 and a beta of 1.14. The company has a quick ratio of 3.01, a current ratio of 3.71 and a debt-to-equity ratio of 0.58.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.16 by $0.49. The firm had revenue of $534.13 million during the quarter, compared to the consensus estimate of $507.23 million. Jazz Pharmaceuticals had a net margin of 32.99% and a return on equity of 27.72%. The company’s revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.49 EPS. Equities research analysts predict that Jazz Pharmaceuticals will post 13.14 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. lifted its holdings in shares of Jazz Pharmaceuticals by 410.7% in the fourth quarter. Macquarie Group Ltd. now owns 14,300 shares of the specialty pharmaceutical company’s stock worth $1,772,000 after buying an additional 11,500 shares in the last quarter. First Hawaiian Bank lifted its holdings in shares of Jazz Pharmaceuticals by 144.4% in the first quarter. First Hawaiian Bank now owns 782 shares of the specialty pharmaceutical company’s stock worth $112,000 after buying an additional 462 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in shares of Jazz Pharmaceuticals in the first quarter worth $25,000. We Are One Seven LLC lifted its holdings in shares of Jazz Pharmaceuticals by 98.8% in the first quarter. We Are One Seven LLC now owns 4,931 shares of the specialty pharmaceutical company’s stock worth $704,000 after buying an additional 2,450 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB lifted its holdings in shares of Jazz Pharmaceuticals by 12.9% in the first quarter. Rhenman & Partners Asset Management AB now owns 187,171 shares of the specialty pharmaceutical company’s stock worth $26,756,000 after buying an additional 21,353 shares in the last quarter. 89.99% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: What is a good dividend yield?

The Fly

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.